- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01707030
Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
As many as 80% of Veterans with the hepatitis C virus (HCV) engage in harmful drinking. This is a major health challenge given that even light and moderate alcohol consumption can worsen the course and consequences of HCV and can be a barrier to receiving antiviral therapy. In response, the VA Uniform Mental Health Services Package has made it a priority that HCV and other ambulatory clinics provide evidence-based mental health services to all Veterans engaging in harmful drinking within two week (but preferably the same day as the clinic visit). The investigators' CREATE partners, the VA Office of Mental Health Services, VA Operations (10N), and the VA Office of Public Health, are strongly committed to achieving this standard throughout the Veterans Health Administration (VHA). However, the cost and organizational challenges to meeting this mandate in HCV clinics are enormous, but may be surmountable through the use of self-directed technology that minimizes demands on scarce staff time.
The primary objective of this study is to implement and evaluate a web-based brief alcohol intervention (BAI) for treating Veterans with HCV and seeking care at two VA HCV clinics - Veterans Affairs Palo Alto Health Care System (VAPAHCS) and San Francisco Veterans Affairs Medical Center (SFVAMC). This study will have three aims: First (Aim 1), the investigators plan to assess patient, provider, and system factors that may impact the initial adoption of this intervention in two VA HCV clinics. These data will result in the development of a protocol for the initial implementation of the web-based BAI at the investigators' two study sites. A secondary aim will involve obtaining patient and provider feedback on an existing web-based BAI (see www.bmi-aft.org, VA Intranet Only) to help inform its redesign for use with this population. Second (Aim 2), the investigators will implement and examine the effectiveness of a web-based BAI in two HCV clinics to reduce alcohol consumption in Veterans with HCV at three- and six-months post-treatment. Third (Aim 3), the investigators will conduct a budget impact analysis to estimate the short-term costs (1-3 years) of adoption and diffusion of the web-based BAI and the trajectory of health care spending for study participants.
This mixed-methods study will utilize qualitative and quantitative methods to achieve its three primary aims. To address aim 1, qualitative interviews will be used to collect data that will inform the initial implementation and re-versioning of a web-based BAI for use in two HCV clinics located at the Palo Alto and San Francisco. To address aim 2, the investigators will use a randomized, hybrid (type 1) design with patient level clinical outcome data and formative evaluation data collected to examine the effectiveness of the web-based BAI. "Hybrid" designs also integrate formative evaluation into experimental designs to identify factors that impact the effectiveness of implementation efforts. Formative evaluation (e.g., site visits, clinic observation, and interviews with staff and patients) will be used to improve the adoption of the web-based BAI at both sites and to provide evidence-based guidance to the investigators' CREATE operational partners for nationwide implementation. To address aim 3, the investigators will conduct a budget impact analysis to estimate the short-term costs (1-3 years) of adoption and diffusion of the web-based BAI and the trajectory of health care spending for study participants. The investigators plan to collect several types of utilization data, including outpatient, inpatient, and pharmacy utilization, and calculate total dollars.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304-1290
- VA Palo Alto Health Care System, Palo Alto, CA
-
San Francisco, California, United States, 94121
- San Francisco VA Medical Center, San Francisco, CA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be a US military veteran.
- Over the age of 17 with liver disease.
- Must be receiving care at a VA liver clinic.
Exclusion Criteria:
- Those with no current or historical use of alcohol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAI Arm
Receiving a web-based brief intervention for alcohol problems
|
Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
All patients will be receiving care in a Hepatitis C clinic.
In some cases clinicians may counsel them on alcohol problems.
|
Active Comparator: Usual Care
In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
|
All patients will be receiving care in a Hepatitis C clinic.
In some cases clinicians may counsel them on alcohol problems.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Days of Unhealthy Alcohol Consumption
Time Frame: Baseline, 3 months, and 6 months
|
The number of days on which alcohol was consumed beyond recommended levels in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Change in Drinking Days
Time Frame: Baseline, 3 months, and 6 months
|
The number of days on which alcohol was consumed at any level in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Drinks Per Drinking Day
Time Frame: Baseline, 3 months, and 6 months
|
The number of standard drinks (0.5 ounce ethanol equivalent) consumed on those days that an individual drank in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Change in Symptoms of Psychological Distress (PHQ-9)
Time Frame: Baseline, 3 months, and 6 months
|
Symptoms of psychological distress will be measured using the Patient Health Questionnaire (PHQ-9).
The PHQ-9 provides an assessment of depression severity.
The minimum value is 0 and the maximum value is 27.
Lower scores are better.
The reliability, validity, and clinical utility of the PHQ-9 instrument are well-established.
|
Baseline, 3 months, and 6 months
|
Change in SF-12 Physical Health Composite
Time Frame: Baseline, 3 months, and 6 months
|
The Short Form-12 (SF-12) is a 12-item health survey based on the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) designed to assess two component health status summary scales (physical and mental component summaries) in the general U.S. population .
The SF-12 has demonstrated good internal consistency reliability and construct validity.
This reflects the physical health component of the SF-12.
Scores range from 0-100 and higher scores are better.
|
Baseline, 3 months, and 6 months
|
Change in Additional Care
Time Frame: Baseline and 12 months
|
Total costs in dollars of all VA and non-VA inpatient, outpatient and pharmacy costs.
|
Baseline and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in SF-12 Mental Health Composite
Time Frame: Baseline, 3 months, and 6 months
|
The Short Form-12 (SF-12) is a 12-item health survey based on the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) designed to assess two component health status summary scales (physical and mental component summaries) in the general U.S. population.
The SF-12 has demonstrated good internal consistency reliability and construct validity.
This reflects the mental health component of the SF-12.
Scores range from 0-100 and higher scores are better.
|
Baseline, 3 months, and 6 months
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22-35. doi: 10.1080/10550887.2016.1100960. Epub 2015 Oct 14.
- Cucciare MA, Timko C. Bridging the gap between medical settings and specialty addiction treatment. Addiction. 2015 Sep;110(9):1417-9. doi: 10.1111/add.12977. No abstract available.
- Cucciare MA, Cheung RC, Rongey C. Treating substance use disorders in patients with hepatitis C. Addiction. 2015 Jul;110(7):1057-9. doi: 10.1111/add.12893. Epub 2015 Mar 27. No abstract available.
- Timko C, Kong C, Vittorio L, Cucciare MA. Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review. J Clin Nurs. 2016 Nov;25(21-22):3131-3143. doi: 10.1111/jocn.13244. Epub 2016 May 3.
- Cucciare MA, Jamison AL, Combs AS, Joshi G, Cheung RC, Rongey C, Huggins J, Humphreys K. Adapting a computer-delivered brief alcohol intervention for veterans with Hepatitis C. Inform Health Soc Care. 2017 Dec;42(4):378-392. doi: 10.1080/17538157.2016.1255628. Epub 2017 Jan 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Digestive System Diseases
- Alcohol-Related Disorders
- Substance-Related Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Alcoholism
- Hepatitis
- Hepatitis A
- Hepatitis C
Other Study ID Numbers
- CRE 12-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
Clinical Trials on Web-Based Brief Alcohol Intervention
-
Cardenal Herrera UniversityCompleted
-
Northwestern UniversityWithdrawnIndividuals at Risk for DepressionUnited States
-
Taipei Medical UniversityRecruitingInfertility | Heart Rate Variability | BiofeedbackTaiwan
-
NYU Langone HealthStanford University; Shaare Zedek Medical CenterCompletedAnxiety Disorders | Major Depression | Post Traumatic Stress DisorderIsrael
-
Taipei Medical UniversityNot yet recruitingParenting | Psychological Distress | Self Efficacy
-
Heidelberg UniversityCompetence Network for Congenital Heart DefectsRecruitingCongenital Heart Disease | Emotional RegulationGermany
-
Milton S. Hershey Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertensionUnited States
-
Hong Kong Baptist UniversityCompletedPhysically Well But WorriedHong Kong
-
Georgetown UniversityAlbert Einstein College of Medicine; University of MichiganCompletedTobacco Cessation | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Virus, Human Immunodeficiency | Tobacco-Use DisorderUnited States
-
SangathCompletedHazardous DrinkingIndia